Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a bile acid pill boost your gut bacteria?

NCT ID NCT07499414

Knowledge-focused Sponsor: University of Reading Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a bile acid supplement called 7-keto lithocholic acid (7-KLCA) can change the types of bacteria living in the gut and improve health markers like blood sugar and cholesterol. Researchers will give the supplement to 40 healthy adults aged 18 to 65 for 12 weeks and measure changes in stool and blood samples. The goal is to learn if this supplement can help regulate metabolism and potentially lower disease risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Volunteer is healthy (good physical and mental condition, disease-free, with haemoglobin levels between 138 - 172 g/L for male and between 121 and 151 g/L for female) at the time of pre-examination * Volunteer is aged ≥ 18 to ≤ 65 years for the duration of the study * Volunteer is able and willing to comply with the study instructions * Volunteer is suitable for participation in the study according to the investigator/study personnel * Volunteer is able to give informed consent * Volunteer must be following a non-restrictive diet according to the investigator/study personnel (no vegan, keto or fasting diets) * Volunteer has not consumed pro- or prebiotic supplements or food products for a minimum of 4 weeks prior to starting the intervention. * Volunteer has no gastrointestinal disorders Exclusion Criteria: * No command of any local language * Gastrointestinal disorders including IBS, IBD or other conditions that might affect the gut environment * Food allergies or intolerances * Using drugs (e.g. antibiotics) influencing gastrointestinal function (12 weeks before intervention) * Use of laxatives * Clinically significant diabetes (plasma glucose test, fasting blood glucose \> 6.5 mmol/l (120 mg/dL) * Volunteers currently involved or will be involved in another clinical/ food study for the duration of this study * History of drug (pharmaceutical or recreational) or alcohol abuse. * If participants are pregnant or are lactating * Regular intake of probiotic or prebiotic supplements * Smoker * Those who follow extreme diets (Keto-diet, Atkins diet, vegan) * Those taking prescribed medication for existing health condition(s) * Those with a pacemaker

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hugh Sinclair Unit, Harry Nursten Building, University of Reading, Whiteknights Campus, RG6 6UR

    RECRUITING

    Reading, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.